Our research has, for the first time, demonstrated that the upregulation of ASF1B can simultaneously activate both the PI3K/AKT and ERK1/2 signaling pathways, further underscoring the value of ASF1B as a potential therapeutic target in GC. The gene discussed is MAPK3; the disease is gastric cancer.